B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.
Origin Therapeutics has completed an investment in Clairvoyant Therapeutics which will now proceed with a Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use...
Clinilabs Drug Development Corporation has begun enrolment in a Phase 1/2a clinical trial of Cybin’s CYB003 for the treatment of major depressive disorder (MDD).
Filament Health has confirmed it has begun dosing in the first FDA-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.
Results from the largest longitudinal study investigating the practice of microdosing psilocybin for mental health, and one of the few to use a control group, have...
Cybin has confirmed that it has received a “may proceed letter” and Investigational New Drug Application (IND) clearance from the U.S.
Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including autoimmune disorders.
Mindset Pharma and Canada’s top psychiatric research hospital, CAMH, have entered into a collaboration to build the molecular profile of MSP-1014 compared to psilocybin.
Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.